April 5, 2010 – Patient enrollment was recently completed in the Small Vessel and Long Lesion trials of the ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
March 26, 2010 – Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-elevated ...
March 26, 2010
Feature | Dave Fornell
Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to ...
March 24, 2010
March 15, 2010 — Results from the PERSEUS clinical program demonstrate positive safety and efficacy outcomes in ...
March 18, 2010
March 15, 2010 — Investigators reported the long-term follow-up of the largest randomized comparison between the ...
March 17, 2010
March 17, 2010 – New data released at the American College of Cardiology Scientific Session this week showed ...
March 17, 2010
March 8, 2010 – A self-expanding and disconnectable stent today gained CE mark approval in Europe to treat acute ...
March 08, 2010
March 8, 2010 – Six-month follow-up data on the Stentys drug-eluting and bare metal stents showed a 4 percent ...
March 08, 2010March 5, 2010 – Experts will lead an evening symposium during ACC 2010 that will cover the latest clinical and ...
March 08, 2010February 11, 2010 – Former president Bill Clinton received two coronary stents today after being admitted to the ...
February 11, 2010
February 2, 2010 – Data published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrate good safety ...
February 02, 2010February 1, 2010 – Three patent disputes between Boston Scientific Corp. and Johnson & Johnson (J&J) were settled ...
February 01, 2010
January 25, 2010 – Trials for a stent that attracts endothelial progenitor cells show positive results in ...
January 25, 2010
January 8, 2010 – Japanese regulatory officials this week cleared the XIENCE V Everolimus-Eluting Coronary Stent ...
January 07, 2010
January 5, 2010 – In vivo and in vitro data released yesterday shows a new bioresorbable stent platform allows for ...
January 05, 2010© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now